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A stereoselective and enantiodivergent strategy for the construction of δ-lactams is described. 
The strategy utilizes chiral malonic esters prepared from enantiomerically enriched mono esters 
of disubstituted malonic acid. A cyclization occurs with the selective displacement of a 
substituted benzyl alcohol as the leaving group. The resulting δ-lactams are then converted into 
nipecotic acid analogues using straightforward transformations. The resulting nipecotic acid 
analogues proved capable organocatalysts in Mannich reactions. 





1. Introduction  
δ-Lactams constitute an important class of compounds in 
synthetic chemistry and biology. They are often found in 
important building blocks of a variety of biologically intriguing 
natural products and as key intermediates in many potent 
bioactive compounds.1-4 In addition, δ-lactams are useful 
precursors to piperidine analogues that are essential 
pharmacophores in a number of medicinal compounds currently 
on the market or in advanced clinical studies.3, 5-8  One of the 
most important classes of the piperidine family is the piperidine-
3-carboxylic acids, otherwise known as derivatives of nipecotic 
acid.  These nipecotic acid analogues are important structural 
motifs in several natural and synthetic bioactive molecules.1, 6-10 
Hence, it is important to have a concise and efficient synthetic 
strategy to prepare δ-lactams in order to construct a variety of 
nipecotic acid analogues.   
Recently a number of synthetic strategies have been established 
to prepare δ-lactams. Some of these strategies include N-
heterocyclic catalyzed intramolecular amidations,11 palladium 
catalyzed intramolecular amidations,12 aza-Diels-Alder 
reactions,13 intramolecular lactone-amine coupling,4 gold 
catalyzed intramolecular C-C couplings of β-ketoamide to 
unactivated alkenes,14 and palladium catalyzed intramolecular 
hydroamidations of alkynes.15 There have also been several 
methods detailing the enantioselective synthesis of δ-lactams 
through ring closing metathesis reactions of enantiomerically 
pure precursors,16 nitrilase catalyzed ring expansion of 
aziridines,17 and the use of organophosphorus reagents as 
organocatalysts.18 Unlike δ-lactams, there are few reports 
detailing the asymmetric synthesis of nipecotic acid analogues; 
many of these strategies rely on functional group modifications 
of preformed nicotinic acids or nipecotic acid derivatives.9, 10, 19, 20 
However, the asymmetric synthesis of piperidine derivatives 
utilizing a stereoselective cyclization approach is surprisingly 
rare. To the best of our knowledge, Shintani et al. is the first to 
report a synthesis of diastereomerically enriched nipecotic acid 
analogues through a palladium catalyzed decarboxylative 
cyclization.9 Therefore, there is a need for additional 
straightforward methods capable of preparing enantiomerically 
enriched nipecotic acid derivatives.  
We have recently demonstrated that γ-lactams can be readily 
prepared by a stereoselective cyclization strategy.21 These 
corresponding γ-lactams were then readily converted into highly 
optically enriched β-proline derivatives.21 Hence, we wanted to 
employ this cyclization strategy to prepare δ-lactams in a 
stereoselective manner. 
2. Results and Discussion 
Recently, we have reported a Pig Liver Esterase (PLE) catalyzed 
asymmetric hydrolysis of the prochiral malonic ester 1.22 This 
biocatalytic hydrolysis of 1 resulted in chiral malonic acid-ester 2 
with high enantiomeric purity (97% ee), and good yields (71%) 
as shown in the Scheme 1. The enantiomerically enriched 
malonic acid-ester 2 was determined to be predominantly the (R)-
enantiomer by synthetic means. The acid ester 2 was then 
converted into benzyl ester 3. In our previous study, we 
witnessed that the para-NO2-benzyl ester readily undergoes 
stereoselective cyclization upon removal of the phthalimide 
protecting group. Upon treatment of 3 with hydrazine hydrate, a 
cyclization took place resulting in δ-lactams 4a, and 4b as shown 
in Scheme 1. The ratio of 4a:4b was 60:1 as determined by 1H-
NMR. Therefore, the results show a high propensity towards 
cyclization along with a high selectivity to form δ-lactam 4a.  
 
 
Scheme 1. Synthesis of -lactams 
 
The strategy illustrated in Scheme 1 shows a straightforward 
approach whereby the manipulation of this type of ester allows 
for a high level of cyclization control. This demonstrates a simple 
strategy that can be very useful in the construction of δ-lactams 
and their derivatives.  
 We decided to further explore this cyclization strategy to obtain 
4b as the major product.  The ability to construct 4b as the major 
product would provide access to a useful enantiodivergent 
strategy to prepare δ-lactams. However, in our previous study a 
Hammet study demonstrated the difficulties in acquiring 4b as 
the major product simply by exploiting the electronic factors 
through substituted benzyl esters. In order to address this issue, 
we synthesized diester 5 from 2 to introduce steric congestion as 





























Scheme 2. Selective cyclization proving access to (S)-δ-lactam 
 
From a steric congestion standpoint, the ethyl ester in 5 should be 
more accessible towards nucleophilic attack by the free amine. 
Upon treatment with hydrazine, 6a was obtained as the only 
product and there was no indication of the formation of 6b as 
indicated by 1H-NMR.  6a is a derivative of 4b with the same 
absolute stereochemistry as 4b. Therefore, introduction of steric 
hindrance gives rise to a highly stereoselective, and potentially 
stereospecific, cyclization strategy to prepare (S)-δ-lactams. To 
the best of our knowledge, this is the first time an 
enantiodivergent strategy has been optimized to prepare such δ-
lactams.  
Over the last few years, Cα-methyl-nipecotic acid has served as 
an important structural entity in a number of synthetic and natural 
therapeutic lead compounds. For example, a group of scientists 
from Merck have discovered a potent NK1 receptor antagonist, 
where (R)-Cα-methyl-nipecotic acid is used as an essential 
building block.7 Nisho et al. have come up with dipeptidyl 
peptidase IV inhibitors consisting of (R)-Cα-Methyl-nipecotic 
acid derivative serving as pharmacophore.5, 6 Despite a number of 
practical applications, asymmetric synthesis of Cα-methyl-
nipecotic acid have been rarely reported in recent years. We 
wanted to demonstrate the potential impact of this cyclization 
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strategy by utilizing the δ-lactams to construct enantiomerically 
pure nipecotic acid analogues. Upon close inspection of 4a and 
6a, it was conceived that the corresponding nipecotic acid 
analogues could be prepared by the selective reduction of the δ-
lactam to a piperidine ring.  This would allow us to prepare both 
enantiomers of Cα-methyl-nipecotic acid analogues and establish 




Scheme 3. Synthesis of (R)-Cα-methyl-nipecotic acid analogue 
 
To accomplish the asymmetric synthesis of (R)-Cα-methyl-
nipecotic acid 11, we started with the enantiomerically enriched 
δ-lactam 4a as shown in Scheme 3. First, δ-lactam 4a was benzyl 
protected to give 7 in good yield (81%). Then the N-benzylated 
lactam 7 was converted into thiolactam 8 employing Lawesson's 
reagent in good yield (80%). Thiolactam 8 was selectively 
reduced to the piperidine derivative 9 utilizing the Raney-Ni 
desulphurization technique in good yield (78%) without further 
purification. The saponification of 9 resulted in the N-benzylated-
nipecotic acid analogue 10 in good yield (88%) requiring no 
further purification. Finally, 10 was fully deprotected by 
hydrogenolysis of the benzyl group resulting in pure Cα-methyl-
nipecotic acid 11 without further purification and in good yield 
(93%). Therefore, the (R)-nipecotic acid analogue was achieved 
in five overall steps requiring little purification and in very good 
overall yield (41%). 
At this point, we wanted to use the (S)-δ-lactam 6a as the key 
intermediate in the preparation of (S)-nipecotic acid analogue 17 
as shown in the Scheme 4. Lactam 6a was converted into N-
benzyl protected lactam 12 in very good yield (80%). In the next 
step we discovered that the tert-butyl ester was not tolerated 
under the conditions utilized to prepare the thiolactam. To 
circumvent this problem, the tert-butyl ester was cleaved and 
reprotected as methyl ester 13 in one pot (89%). Lactam 13 was 
then converted into thiolactam 14 utilizing Lawesson's reagent in 
good yield (78%). Thiolactam 14 was subject to Raney-Ni 
desulphurization resulting in (S)-piperidine-3-carboxylate 15 in 
good yield (80%). Saponification of 15 resulted in (S)-N-
benzylated nipecotic acid derivative 16 in 75% yield.  Compound 
16 was subjected to hydrogenation to achieve (S)-nipecotic acid 
analogue 17 in very good yield (92%). The specific rotation 
confirms 17 as the enantiomer of 11. This success provides 
access to the (S)-nipecotic acid analogue 17 with a limited 




Scheme 4. Synthesis of (S)-Cα-methyl-nipecotic acid analogue 
 
With the nipecotic acids in hand, we wanted to explore the 
organocatalytic efficiency of (R)-Cα-methyl-nipecotic acid 11 in 
Mannich type reactions. To the best of our knowledge, Zhang et 
al. are the first to test (R)-nipecotic acid as a catalyst in Mannich 
reactions.23 They observed (R)-nipecotic acid to produce the 
Mannich product with moderate anti-selectivity (anti/syn = 78 : 
22) and enantioselectivity (anti = 36% ee, syn =12% ee).23 In this 
context, we wanted to envisage if the enhanced rigidity employed 
by an additional methyl group in 11 would play a role in the 
selectivity of the resulting Mannich product. We performed the 
same Mannich reaction tested by Zhang et al. as shown in 
Scheme 5 employing 30 mol % of 11 as an organocatalyst.23  The 
reaction  was complete within 12 h and the Mannich product was 
obtained upon purification in reasonable yield (78%). Chiral 
HPLC (Figure 1) and 1H-NMR established the product as 
moderately anti-selective (anti/syn = 72.5:27.5), and with slightly 




Scheme 5. Cα-Methyl-nipecotic acid catalyzed Mannich reaction 
 
It is evident from the experimental data that Cα-methyl nipecotic 
acid 11 provides the Mannich product with approximately the 
same anti/syn-selectivity as nipecotic acid, but with slightly 
diminished enantiomeric excess for the anti-Mannich product. 
Based on the obtained result, we propose that Cα-methyl-
nipecotic acid 11 prefers the (S)-cis-enamine and has a slight 














Figure 1. Chiral HPLC (Daicel Chairalcel AS-H, hexanes /i- 
PrOH = 99:1, 1.0 mL/min, λ = 254 nm) of (R)-Cα-
methylnipecotic acid 11 catalyzed Mannich product. 
 
 
Figure 2. Proposed transition state of Cα-methyl-nipecotic acid 
catalyzed Mannich reaction 
3. Conclusions 
We have optimized a highly enantioselective and 
enantiodivergent cyclization strategy for the preparation of δ-
lactams starting with the enantiomerically enriched common 
intermediate 2. This is the first reported strategy in which δ-
lactams are prepared in a highly stereoselective manner simply 
by regulating steric and electronic factors. We believe that this 
straightforward approach will provide access to a wide variety of 
enantiomerically enriched δ-lactams. We have demonstrated that 
both the (R)- and (S)-δ-lactams can be readily converted into their 
respective nipecotic acid analogues. This success provides access 
to a concise and enantiodivergent approach to potentially achieve 
a number of highly demanding enantiomerically enriched 
nipecotic acid analogues. We have explored Cα-methyl-nipecotic 
acid as a catalyst in the Mannich reaction. Our initial results 
show that Cα-methyl-nipecotic acid provides a similar 
diastereomeric excess as nipecotic acid but with diminished %ee 
(36% ee to 26% ee) for the anti-diastereomers. We suspect that 
the increased rigidity of the piperidine ring introduced by an 
additional methyl group is responsible for the reduced %ee. 
 
4. Experimental  
 
Synthesis of diethyl-2-[3-(1,3-dioxoisoindolin-2-yl)-2-
methylmalonate 1: Diester 1 was obtained from the reaction 
between 10 g of diethyl-2-methylmalonate (57.4 mmol), 15.40 g 
(57.4 mmol) of N-(bromopropyl)-phthalimide and 2.74 g (68.9 
mmol) of NaH following a literature procedure. An amount of 
12.8 g (35.4 mmol, 62%) pure 1 was obtained as colorless liquid 
upon purification by column chromatography (30 : 70 




(ethoxycarbonyl)-2-methylpentanoic acid 2: Compound 2 was 
prepared from 10 g of 1 (28 mmol) employing pig liver esterase 
(PLE) catalyzed desymmetrization following a literature 
procedure.22 The resulting half-ester was purified by flash 
chromatography (40:60 EtOAc/hexanes) to give 6.60 g of the 
product as a colorless liquid (20 mmol, 68%). The % ee was 
determined to be 97% by chiral HPLC (Diacel Chiralpak OJ-H, 
4% iPrOH/hexanes, flow rate = 1 mL/min, λ = 305 nm) Rt(S) = 
54.9 min (Area = 130.13), Rt(R) = 58.8 min (Area = 7770.41). Rf 
= 0.22 (40% EtOAc/hexanes). IR (cm-1) = 2983, 2937, 1773, 
1747, 1697. []D
24 = + 5.8 (c 2, MeOH). 1H-NMR (CDCl3, 400 
MHz): δ 7.85 (m, 2H), 7.73 (m, 2H), 4.21 (q, 2H, J = 7Hz), 3.71 
(t, 2H, J = 7Hz), 1.93 (m, 2H), 1.71 (m, 2H), 1.45 (s, 3H), 1.26 (t, 
3H, J = 7Hz). 13C-NMR (CDCl3, 100 MHz): δ 176.0, 172.0, 
168.0, 134.0, 132.0, 123.0, 62.0, 53.0, 38.0, 33.0, 24.0, 20.0, 
14.0. HRMS [C17H19NO6Na
+] calcd = 356.3256, found = 
356.3253. 
Synthesis of (S)-1-ethyl 3-(4-nitrobenzyl) 2-[3-(1,3-
dioxoisoindolin-2-yl)propyl]-2-methylmalonate 3:  A 250 mL 
round-bottom flask was charged with 6.41 g of 2 (19 mmol), 2.62 
g of K2CO3 (19 mmol), 75 mL of anhydrous DMF, and a stir bar. 
A solution of the 4-nitrobenzyl bromide (17.1 mmol) in 20 mL of 
anhydrous DMF was slowly added over 15 min. The reaction 
was allowed to stir approximately 12 h under a nitrogen 
atmosphere. The reaction mixture was then diluted with 100 mL 
of water, and the resulting mixture was washed with Et2O (3 × 
150 mL). The combined ether layer was washed with water (8 × 
150 mL) and brine (2 × 100 mL), dried over MgSO4, filtered, and 
the solvent was removed under reduced pressure. The product 
was isolated by flash chromatography (30% EtOAc/hexanes), 
giving 8.10 g (17.4 mmol, 87%) pure 3 as a white solid.  Rf = 0.1 
(30% EtOAc/hexanes).   []D
23 = -33.0 (c 1, CH2Cl2). mp = 66 
OC. IR (cm-1) = 2982, 1775, 1710. 1H-NMR (CDCl3, 400 MHz): 
δ  8.19 (d, 2H, J = 8.32 Hz), 7.81 (m, 2H), 7.72 (m, 2H), 7.46 (d, 
2H, J = 8.32 Hz), 5.22 (m, 2H), 4.15 (q, 2H, J = 7 Hz), 3.68 (t, 
2H, J = 7 Hz), 1.95 (m, 2H), 1.65 (m, 2H), 1.44 (s, 3H), 1.18 (t, 
3H, J = 7 Hz). 13C-NMR (CDCl3, 100 MHz): δ 171.5, 168.2, 
148.7, 134.0, 132.0, 128.2, 124.0, 123.3, 65.2, 61.4, 58.5, 53.0, 
37.8, 33.0, 24.0, 20.0, 18.2, 13.6. HRMS [C24H24N2O8Na
+] calcd 
= 491.1425, found = 491.1422.  
Synthesis of (R)-ethyl 3-methyl-2-oxopiperidine-3-
carboxylate 4a:  A volume of 1.8 mL (20 mmol) 35% hydrazine 
in water was added to a solution of 5.10 g (11 mmol) of 3 in 50 
mL of MeOH. The mixture was heated at reflux overnight. A 
white precipitate was observed within 1 h of reflux. The reaction 
mixture was allowed to cool to room temperature, and the 
resulting mixture was filtered through a polypropylene 0.2 mm 
pore size syringe filter. An amount of 1.36g (9.9 mmol) of K2CO3 
was added to the filtrate. The solution was allowed to reflux for 6 
h, after which the solvent was evaporated under reduced pressure. 
The resulting residue was taken up in CH2Cl2 and washed with 
water. The organic layer was dried over MgSO4, evaporated 
under reduced pressure, and purified by column chromatography 
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using 60% Hexanes/EtOAc giving 1.5g (8.3 mmol, 75%) of 4 as 
a white solid. Rf = 0.35 (30% EtOAc/hexanes).   []D
24  = + 29.2 
(c 1, CH2Cl2). mp = 65 
OC. IR (cm-1) = 3219.6, 2940.4, 2871.9, 
1726.5, 1655.5. 1H-NMR (CDCl3, 400 MHz): δ 6.25 (bs, 1H), 4.2 
(m, 2H), 3.36 (m, 2H), 2.26 (m, 1H), 1.84 (m, 2H), 1.73 (m, 1H), 
1.50 (s, 3H), 1.27 (t, 3H, J = 7 Hz).  13C-NMR (CDCl3, 100 
MHz):  δ 173.6, 172.0, 61.2, 50.3, 42.3, 33.0, 22.4, 90.4, 14.0. 
HRMS [C9H15NO3Na
+] calcd = 208.0944, found = 208.0944. 
Synthesis of (S)-1-tert-butyl 3-ethyl 2-methyl-2-(3-(1,3-
dioxoisoindolin-2-yl)propyl)malonate 5: A volume of 600 µL 
conc. H2SO4 was added to a solution of 2 g of 2 (6 mmol) in 30 
mL of CH2Cl2 in a 100 mL sealed tube. The solution was cooled 
to -7 oC. A volume of 6 mL of condensed isobutylene was added 
to the solution. The tube was sealed tightly and allowed to stir 
overnight at rt. The tube was uncapped and allowed to stir for 2h 
at ambient pressure to allow excess isobutylene to evaporate. The 
solution was diluted with 30 mL of CH2Cl2 and gently washed 
three times with 1M NaOH (50 mL). The CH2Cl2 layer was dried 
over MgSO4, evaporated under reduced pressure, and 
chromatographed (40% EtOAc/hexanes), giving 2 g (5.1 mmol, 
87%) of 5 as a white solid. Rf = 0.53 (40% EtOAc/hexanes).  
[]D
23  = -5.2 (c 1, MeOH). MP = 77 OC.  IR (cm-1): 2976.2, 
2936.4, 1771.3, 1712.5. 1H-NMR (CDCl3, 400 MHz): 7.84 (m, 
2H), 7.71 (m, 2H), 4.18 (m, 2H), 3.74 (m, 2H), 1.91 (m, 2H), 
1.61 (m, 2H), 1.48 (s, 9H), 1.39 (s, 3H), 1.28 (t, 3H, J = 7 Hz). 
13C-NMR (CDCl3, 100MHz) 172.3, 171.03, 168.3, 134.0, 132.1, 
123.2, 81.5, 61.1, 54.0, 38.1, 34.7, 28.0, 25.3, 20.0, 14.0. HRMS 
[C21H27NO6Na
+]: calcd = 412.1730, found = 412.1730. 
Synthesis of (S)-tert-butyl 3-methyl-2-oxopiperidine-3-
carboxylate 6a: A volume of 398 µL (4.4 mmol) 35% hydrazine 
in water was added to a solution of 1.50 g (4 mmol) of 5 in 25 
mL of MeOH. The mixture was heated at reflux overnight. A 
white precipitate was observed within an hour of reflux. The 
reaction mixture was allowed to cool to RT and the solution was 
filtered. An amount of 0.55 g of K2CO3 (4 mmol) was added to 
the filtrate, and the solution was allowed to reflux for another 6 h. 
The solvent was evaporated under reduced pressure and the 
residue taken up in CH2Cl2. The resulting mixture was washed 
with water and the organic layer was dried over MgSO4, 
evaporated under reduced pressure, and chromatographed using 
30% hexanes/EtOAc giving 0.62 g (3 mmol, 75%) of 6a as a 
white solid. Rf (6a) = 0.27 (30% hexanes/EtOAc). mp = 130 
OC. 
IR (cm-1): 3218.5, 2975.6, 2938.5, 2870.8, 1726.7,1660.3. []D
23 
= -16.2 (c 1, CH2Cl2). 
1H-NMR (CDCl3, 400 MHz): 6.28 (bs, 
1H), 3.61 (m, 2H), 2.2 (m, 1H), 1.8 (m, 2H), 1.61 (m, 1H), 1.42 
(s, 12H). 13C-NMR (CDCl3, 100 MHz): 174.2, 173.9, 83.0, 51.0, 
43.0, 34.0, 28.0, 20.0, 14.0. HRMS [C11H19NO3Na
+]: calcd = 
236.1257, found = 236.1258. 
Synthesis of (R)-ethyl 1-benzyl-3-methyl-2-oxopiperidine-3-
carboxylate 7: A solution of 0.30 g (1.6 mmol) of 4a in 10 mL 
of anhydrous THF was added slowly to a suspension of 0.046 g 
NaH (1.92 mmol) in 10 mL of THF at 0 °C under an N2 
atmosphere. The reaction mixture was allowed to stir for 5 min. 
A volume of 210 µL (1.76 mmol) of BnBr was added dropwise 
to the reaction mixture at 0 °C. The reaction mixture was allowed 
to stir for 10 min at 0 °C and then allowed to warm to rt. The 
reaction was continued for 1h at rt. A volume of 6 mL of dry 
DMF was added to the reaction mixture, which continued to stir 
for 2 h. The reaction mixture was poured into 15 mL of H2O. The 
water layer was extracted with Et2O (3 × 25 mL). The combined 
ether layer was washed with water (3 × 10 mL), dried over 
MgSO4, evaporated under reduced pressure, and 
chromatographed (gradient, 15−20% EtOAc/hexanes) giving 
0.36 g (1.3 mmol, 81%) of pure 7 as a colorless oil. Rf = 0.3 
(20% EtOAc/hexanes).  []D
24  = + 62.6 (c 2, CH2Cl2). IR (cm
-1) 
= 3219.6, 2940.4, 2871.9, 1726.5, 1655.5. 1H-NMR (CDCl3, 400 
MHz): 7.29 (m, 5H), 5.0 (d, 1H, J = 14.24 Hz), 4.2 (m, 3H), 
3.24 (m, 2H), 2.23 (m, 1H), 1.79 (m, 3H), 1.54 (s, 3H), 1.29 (t, 
3H, J = 7 Hz).  13C-NMR (CDCl3, 100 MHz): δ 173.6, 169.3, 
137.2, 128.5, 127.8, 127.3, 61.4, 50.7, 50.4, 47.3, 33.4, 22.7, 
19.4, 14.2. HRMS [C16H21NO3Na
+] calcd = 298.1413, found = 
298.1411. 
Synthesis of (S)-ethyl 1-benzyl-3-methyl-2-thioxopiperidine-
3-carboxylate 8: A 1.70 g (4.2 mmol) portion of Lawesson’s 
reagent was added to a solution of 1.30 g (4.7 mmol) of 7 in 20 
mL of anhydrous toluene under an N2 atmosphere. The reaction 
mixture was heated to 95 °C and stirred for over 12 h.  The 
reaction completion was verified by TLC (20% EtOAc/hexanes).  
The toluene layer was evaporated under reduced pressure, and 
the residue was chromatographed (20% EtOAc/hexanes) giving 
0.97 g (3.3 mmol, 80%) of 8 as a colorless oil. The conversion of 
lactam 7 to the corresponding thiolactam 8 was confirmed by 
comparing the 13C NMR chemical shift of the lactam 7 carbonyl 
carbon (173.6 ppm) to thiolactam 8 carbonyl carbon (202.5 ppm). 
Rf = 0.3 (20% EtOAc/hexanes).  []D
22  = +75.2 (c 1, CH2Cl2). IR 
(cm-1) = 2936.7, 1731.3, 1506.9. 1H-NMR (CDCl3, 400 MHz): δ 
7.31 (m, 5H), 5.69 (d, 1H, J = 14.37 Hz), 5.04 (d, 1H, J = 14.37 
Hz), 4.23 (m, 2H), 3.43 (m, 2H), 2.28 (m, 1H), 2.01 (m, 1H), 
1.83 (m, 2H), 1.75 (s, 3H), 1.30 (t, 3H, J = 7 Hz).  13C-NMR 
(CDCl3, 100 MHz): δ 202.5, 173.6, 135.0, 129.0, 127.7, 127.5, 
61.5, 57.7, 55.5, 50.4, 32.1, 27.8, 19.4, 14.0. HRMS 
[C16H21NO2SNa
+] calcd = 314.1185, found = 314.1184.   
Synthesis of (R)-ethyl 1-benzyl-3-methylpiperidine-3-
carboxylate 9: A 0.80 g portion of 8 (2.7 mmol) was dissolved in 
20 mL of 4:1 THF/EtOH. A 0.16 g portion of Raney-Ni slurry in 
water (20% by weight) was added to the solution. The solution 
was stirred vigorously under a H2 atmosphere for 6 h, at which 
point the reaction was found to be half-complete by TLC (10% 
hexanes/CH2Cl2). The mixture was continued to stir under an H2 
atmosphere another 6 h.  The reaction was found to be completed 
via TLC to give 0.54 g (2 mmol, 78%) of 9 as a colorless liquid. 
Rf = 0.35 (20% hexanes/CH2Cl2).   []D
21   = + 11.8 (c 1, 
CH2Cl2). IR (cm
-1) = 2939.4, 2795.4, 1725.9. 1H- NMR (CDCl3, 
400 MHz): 7.29 (m, 5H), 4.43 (m, 2H), 3.52 (d, 1H, J = 13.54 
Hz), 3.40 (d, 1H, J = 13.59 Hz), 2.97 (bm, 1H), 2.58 (bm, 1H), 
2.02 (m, 3H), 1.73 (m, 1H), 1.59 (m, 1H), 1.21 (t, 3H, J = 7 Hz), 
1.16 (bs, 1H), 1.13 (s, 3H).  13C-NMR (CDCl3, 100 MHz): 176.5, 
138.2, 128.8, 127.0, 63.1, 62.0, 60.2, 54.0, 43.1, 33.2, 24.0, 23.0, 
14.0. HRMS [C16H23NO2Na
+] calcd = 284.1621, found = 
284.1621. 
Synthesis of (R)-1-benzyl-3-methylpiperidine-3-carboxylic 
acid 10: A 0.125 g portion of crushed LiOH powder (5.2 mmol) 
was added to a solution of 0.46 g (1.7 mmol) of 9 in 20 mL of 3:2 
H2O/EtOH. The reaction was stirred at rt overnight.  The reaction 
was determined to be complete by TLC (5% MeOH/CH2Cl2). 
The mixture was acidified to pH 3 (10% HCl), and the water 
layer was evaporated under reduced pressure giving a colorless 
gummy residue. The gummy residue was triturated with 10% 
MeOH/CH2Cl2 (20 mL x 20), and the MeOH fractions were dried 
over MgSO4. The solvent was removed under reduced pressure 
giving 0.36 g (1.56 mmol, 88%) of 10 as a white solid as verified 
by TLC and staining with bromocresol green. Rf = 0.15 (5% 
MeOH/CH2Cl2).   []D
22   = + 19.0 (c 1, MeOH).  IR (cm-1) = 
3367.5, 2961.4, 1706.1. 1H- NMR (CD3OD, 400 MHz): δ 7.52 
(m, 5H), 4.50 (d, 1H, J = 13.61Hz), 4.17 (d, 1H, J = 13.59 Hz), 
3.60 (d, 1H, J = 13.3 Hz), 3.40 (d, 1H, J = 13.3 Hz), 3.10 (m, 
1H), 2.80 (d, 1H, J = 13.40 Hz), 2.20 (d, 1H, J = 13.40 Hz), 1.98 
(m, 1H), 1.80 (m, 1H), 1.54 (m, 1H), 1.2 (s, 3H). 13C-NMR 
(CD3OD, 100 MHz): δ 178.1, 132.0, 131.2, 130.4, 130.3, 62.1, 
57.7, 55.0, 43.4, 33.0, 24.1, 22.1. HRMS [C14H19NO2Na
+] calcd 
= 256.1308, found = 256.1309. 
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Synthesis of (R)-3-methylpiperidine-3-carboxylic acid (11): 
A 0.30 g (1.3 mmol) portion of 10 was dissolved in 15 mL of 
MeOH and added to 0.06 g Pd/C (20% by weight).  The solution 
was allowed to stir overnight under a H2 atmosphere at rt. The 
resulting mixture was filtered through Celite, and the filtrate was 
evaporated under reduced pressure giving 0.185 g (1.29 mmol, 
93%) of 11 as a white solid. mp = 90 OC,   []D
24   = +1.2 (c 1, 
MeOH), Rf = 0.08 (5% MeOH/CH2Cl2). IR (cm
-1) = 3374.7, 
2959.4, 1706.1. 1H-NMR (CD3OD, 400 MHz): δ 3.53 (d, 1H, J = 
12.56 Hz), 3.28 (m, 1H), 2.97 (m, 1H), 2.83 (d, 1H, J = 12.56 
Hz), 2.19 (d, 1H, J = 12.56 Hz), 1.88 (m, 1H), 1.69 (m, 1H), 1.58 
(m, 1H), 1.27 (s, 3H).  13C-NMR (CD3OD, 100 MHz): δ 178.5, 
50.10, 44.3, 41.4, 33.5, 23.5, 21.0. ESI-MS [C7H13NO2H
+] calcd 
= 143.1, found = 144.1. We could not perform HRMS analysis 
due to the molecular weight being lower than the detection limit 
of the instrument.  
Synthesis of (S)-tert-butyl 1-benzyl-3-methyl-2-oxopiperidine-
3-carboxylate 12: A solution of 1.0 g (4.7 mmol) of 6a in 20 mL 
of anhydrous THF was added slowly to a suspension of 0.14 g 
NaH (5.6 mmol) in 10 mL of THF at 0 °C under an N2 
atmosphere. The reaction mixture was allowed to stir for 5 min. 
A volume of 0.63 µL (5.2 mmol) of BnBr was added dropwise to 
the reaction mixture at 0 °C. The reaction mixture was allowed to 
stir for 10 min at 0 °C and then allowed to warm to rt. The 
reaction was continued for 1 h at rt. A volume of 20 mL of dry 
DMF was added to the reaction mixture, which continued to stir 
for 2 h. The reaction mixture was poured into 15 mL of H2O. The 
water layer was extracted with Et2O (3 × 25 mL). The combined 
ether layer was washed with water (3 × 10 mL), dried over 
MgSO4, evaporated under reduced pressure, and 
chromatographed (gradient, 15−20% EtOAc/hexanes) giving 
1.20 g (3.8 mmol, 80%) of pure 12 as a white solid. Rf = 0.32 
(20% EtOAc/hexanes).   []D
24   = - 64.2 (c 1, CHCl3). mp = 108 
OC IR (cm-1) = 2977.8, 2933.4, 1727.5, 1625.9. 1H-NMR (CDCl3, 
400 MHz): 7.28 (m, 5H), 5.04 (d, 1H, J = 14.54 Hz), 4.16 (d, 1H, 
J = 14.54 Hz), 3.22 (m, 2H), 2.21 (m, 1H), 1.76 (m, 3H), 1.47 
(m, 12H).  13C-NMR (CDCl3, 100 MHz): δ 173.0, 170.2, 137.4, 
128.5, 128.0, 127.3, 81.4, 51.3, 50.5, 47.4, 33.5, 28.0, 22.3, 20.0. 
HRMS [C18H25NO3Na
+] calcd = 326.1726, found = 326.1728. 
Synthesis of (S)-methyl 1-benzyl-3-methyl-2-oxopiperidine-3-
carboxylate 13: A volume of 3 mL TFA was added to a solution 
of 1 g 12 (3.2 mmol) in 25 mL CH2Cl2. The reaction was 
continued to stir over 2 h at ambient temperature. At which point 
the reaction was found to be completed as evident by TLC and 
ESI-MS. The methylene chloride layer was evaporated and the 
residue was dissolved in 20 mL of DMF. An amount of 0.50 g 
(3.6 mmol) K2CO3 was added to the solution, followed by, an 
amount of 0.91 g (6.4 mmol) of CH3I. The reaction was 
continued to stir under N2 atmosphere over 3h at which point the 
reaction was found to be completed by TLC. The reaction 
mixture was poured into 50 mL of H2O. The water layer was 
extracted with Et2O (3 x 50 mL). The combined ether layer was 
extracted with water, washed with brine, dried over MgSO4, and 
evaporated out to dryness giving 0.74 g (2.85 mmol, 89%) of 
pure 13 as a colorless oil.   []D
22   = – 40.0 (c 0.7, CHCl3). Rf = 
0.29 (20% EtOAc/hexanes). IR (cm-1) = 2948.6, 1730.8, 1634.6. 
1H-NMR (CDCl3, 400 MHz) 7.30 (m, 5H), 4.81 (d, 1H, J = 14.27 
Hz), 4.41 (d, 1H, J = 14.27 Hz), 3.74 (s, 3H), 3.24 (m, 2H), 2.25 
(m, 1H), 1.77 (m, 3H), 1.54 (s, 3H). 13C-NMR (CDCl3, 100 
MHz) δ 174.4, 169.8, 137.2, 128.6, 127.8, 127.3, 52.3, 50.7, 
50.5, 47.3, 33.4, 22.9, 19.7. HRMS [C15H19NO3Na
+] calcd = 
284.1257, found = 284.1258. 
Synthesis of (R)-methyl 1-benzyl-3-methyl-2-
thioxopiperidine-3-carboxylate 14: A 1.03 g (2.5 mmol) 
portion of Lawesson’s reagent was added to a solution of 0.70 g 
(2.7 mmol) of 13 in 20 mL of anhydrous toluene under a N2 
atmosphere. The reaction mixture was heated to 95 °C and stirred 
over 12 h.  The reaction completion was verified by TLC (20% 
EtOAc/hexanes).  The toluene layer was evaporated under 
reduced pressure, and the residue was chromatographed (20% 
EtOAc/hexanes) giving 0.58 g (2.1 mmol, 78%) of 14 as 
colorless oil. The conversion of lactam 13 to the corresponding 
thiolactam 14 was confirmed by comparing the 13C-NMR 
chemical shift of the lactam 13 carbonyl carbon (173.6 ppm) to 
the thiolactam 14 carbonyl carbon (202.3 ppm). Rf = 0.33 (20% 
EtOAc/hexanes).   []D
22   = - 15.7 (c 1, CHCl3).
 1H-NMR 
(CDCl3, 400 MHz): δ 7.33 (m, 5H), 5.35 (m, 2H), 3.76 (s, 3H), 
3.42 (m, 2H), 2.30 (m, 1H), 1.92 (m, 3H), 1.75 (s, 3H).  13C-
NMR (CDCl3, 100 MHz): 202.3, 174.1, 135.3, 128.8, 127.7, 
127.5, 58.0, 56.1, 52.7, 50.4, 32.4, 27.7, 19.3. HRMS 
[C15H19NO2SNa
+] calcd = 300.1028, found = 300.1029.   
Synthesis of (S)-methyl 1-benzyl-3-methylpiperidine-3-
carboxylate 15: A 0.40 g portion of 14 (1.4 mmol) was dissolved 
in 20 mL of 4:1 THF/EtOH. A 0.08 g portion of Raney-Ni slurry 
in water (20% by weight) was added to the solution. The solution 
was stirred vigorously under a H2 atmosphere for 6 h at which 
point the reaction was found to be half-complete by TLC (10% 
hexanes/CH2Cl2). The mixture was continued to stir under H2 
atmosphere for another 6 h.  The reaction was found to be 
completed via TLC to give 0.27 g (1.12 mmol, 80%) of 15 as a 
colorless liquid. Rf = 0.33 (20% hexanes/CH2Cl2).   []D
23   = - 
5.0 (c 0.8, CHCl3). IR (cm
-1) = 2954.8, 2794.6, 1729.6. 1H- NMR 
(CDCl3, 400 MHz): 7.26 (m, 5H), 3.66 (s, 3H), 3.53 (d, 1H, J = 
13.01 Hz), 3.40 (d, 1H, J = 13.01 Hz), 2.94 (m, 1H), 2.59 (m, 
1H), 2.09 (m, 2H), 1.92 (m, 1H), 1.73 (m, 1H), 1.60 (m, 1H), 
1.14 (m, 4H).  13C-NMR (CDCl3, 100 MHz): 176.9, 138.6, 128.7, 
127.9, 126.8, 62.9, 61.7, 54.0, 51.4, 43.3, 33.3, 23.9, 22.9. HRMS 
[C15H21NO2Na
+] calcd = 270.1464, found = 270.1466. 
Synthesis of (S)-1-benzyl-3-methylpiperidine-3-carboxylic 
acid 16: A 0.89 g portion of crushed KOH powder (16 mmol) 
was added to a solution of 0.20 g (0.8 mmol) of 15 in 20 mL of 
EtOH. The reaction was allowed to reflux overnight.  The 
reaction was determined to be complete by TLC (5% 
MeOH/CH2Cl2). The mixture was acidified to pH 3 (10% HCl), 
and the water layer was evaporated under reduced pressure 
giving a colorless gummy residue. The gummy residue was 
triturated with 10% MeOH/CH2Cl2 (20 mL x 20), and the MeOH 
fractions were dried over MgSO4. The solvent was removed 
under reduced pressure giving 0.14 g (0.6 mmol, 75%) of 16 as a 
white wax.    []D
22   = - 9.5 (c 1, MeOH).  Characterization data 
of 16 matched that of 10. 
Synthesis of (S)-3-methylpiperidine-3-carboxylic acid 17: A 
0.30 g (1.3 mmol) portion of 10 was dissolved in 15 mL of 
MeOH and added to 0.06 g Pd/C (20% by weight).  The solution 
was allowed to stir overnight under a H2 atmosphere at rt. The 
resulting mixture was filtered through Celite, and the filtrate was 
evaporated under reduced pressure giving 0.185 g (1.29 mmol, 
93%) of 17 as an oil.  []D
24   = -1.5 (c 1, MeOH). 
Characterization data of 17 matched that of 11. 
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